Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Victor Tets is currently prosecuting 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single matter constitutes the entire active workload for the entity at the USPTO. The focus on 1 pending office action suggests a highly targeted approach to securing intellectual property, where all current legal resources are dedicated to a specific application.
The examination is being handled by 1 distinct examiner, SWIFT, CANDICE LEE. As the only official assigned to the portfolio, SWIFT, CANDICE LEE is also the busiest examiner with 1 pending office action under her review. This prosecution is taking place within 1 distinct art unit, which further emphasizes the concentrated nature of the current patent activities in the Biotechnology & Pharmaceuticals field.
For a practitioner, the presence of 1 distinct examiner and 1 distinct art unit for the 1 pending office action simplifies the interaction with the USPTO. There is no requirement to manage different examiner styles or art unit interpretations, as all activity is localized. This Biotechnology & Pharmaceuticals portfolio benefits from a direct line of communication with SWIFT, CANDICE LEE, ensuring a consistent prosecution path for the 1 pending office action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SWIFT, CANDICE LEE | 1 | 56.6% | +37.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18285641 | BIOACTIVE PRODUCTS | SWIFT, CANDICE LEE | — |
| Art Unit | Apps |
|---|---|
| 1657 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18285641 | BIOACTIVE PRODUCTS | SWIFT, CANDICE LEE | 1657 | §102§103§112DP | Non-Final OA | — | Pending | Oct 04, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialVictor Tets has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Candice Lee Swift has the most, with 1 of Victor Tets's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
